Nontuberculous Mycobacteria Market


As per the American Thoracic Society, the number of people living with Nontuberculous Mycobacteria lung disease and newly infected individuals are on the rise, especially among the older age group.
Arikayce, is the first and only medication, which has been approved by FDA for the treatment of Mycobacterium avium complex lung disease.
Some of other drugs that are being evaluated in clinical trials for Nontuberculous Mycobacteria indications include RHB-204 (RedHill Biopharma Ltd.), Thiolanox (NOVOTERIS), Molgradex ( Savara Inc.), and NitricOxide (Beyond Air™) in phase II of clinical trials; and SPR720 (Spero Therapeutics), and MAT2501 (Matinas BioPharma) in phase I.
For more details visit: https://www.delveinsight.com/blog/nontuberculous-mycobacteria-drug-market/